Immunitor Therapy is a Potential Breakthrough Against Tuberculosis
25 Outubro 2010 - 9:29AM
Immune Network Ltd. (Pink Sheets:IMMFF) advises that a clinical
trial of V5 Immunitor oral vaccine was published earlier this month
demonstrating an unexpected powerful effect against tuberculosis,
including multi-drug-resistant tuberculosis (MDR-TB) and
tuberculosis that is complicated by co-infection with HIV and
hepatitis C (HCV). As advised in a September 16, 2010 press
release, the Company has entered into a letter of intent to acquire
Immunitor oral vaccine technology and products, subject to several
conditions including the Company completing its regulatory filings.
V5 Immunitor is an oral vaccine designed and shown to be
clinically effective for managing chronic hepatitis B and hepatitis
C. The anti-tuberculosis effect has been revealed during a
routine clinical trial of V5 in patients with chronic hepatitis C
who happened to have tuberculosis. Not only was V5 effective
on various liver disease endpoints in 19/20 of the patients,
but also, several clinical endpoints associated with TB
co-infection improved significantly during the one-month trial
leading to discharge of 17 of the 20 patients enrolled. These
results were published in the October 2010 edition of Journal of
Vaccines and Vaccination, and are available in full text online at
http://www.omicsonline.org/2157-7560/2157-7560-1-103.php. An
Immunitor press release is available online at
http://www.prweb.com/releases/2010/10/prweb4647254.htm.
Immunitor is continuing its clinical work on V5 and other
products and updates on progress and further trials will be given
accordingly. Immune Network has commenced work toward full
regulatory compliance in Canada and USA so that the acquisition of
Immunitor may proceed as planned.
Further information is available on the web for Immune Network
Ltd. (www.immune-network.com) and for Immunitor
(www.immunitor.com).
The Immune Network Ltd logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8008
Safe Harbor Statement
The information in this release, other than historical
information, may be considered forward-looking statements within
the provisions of the Private Securities Litigation Reform Act of
1995. Projection and other forward-looking statements and
management expectations regarding future events and/or financial
performance of the Company -- although given in good faith -- are
inherently uncertain and actual events and/or results may differ
materially.
CONTACT: Immune Network Ltd.
immff@yahoo.com
Omni Bridgeway (PK) (USOTC:IMMFF)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Omni Bridgeway (PK) (USOTC:IMMFF)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Omni Bridgeway Ltd (PK) da OTCMarkets bolsa de valores: 0 artigos recentes
Mais Notícias de Immune Network Ltd